Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03734627
Other study ID # CRFSJ075 and 0095
Secondary ID 2016-02-CA(9)201
Status Completed
Phase
First received
Last updated
Start date July 1, 2016
Est. completion date July 1, 2021

Study information

Verified date August 2021
Source St. James's Hospital, Ireland
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The incidence of oesophagogastric cancer has increased by 400% since the 1970s in Ireland and the United Kingdom. In addition, refinement of perioperative management and the now widespread use of multimodal protocols for patients with locally advanced disease have significantly improved outcomes for patients with oesophagogastric cancer treatable with curative intent. Despite significant advances in chemoradiotherapy, surgical resection remains the primary curative option. Unintentional weight loss and nutritional complications represent serious concerns for patients after radical resection, even among those who remain free from recurrent disease in the long-term. A study from the Swedish Esophageal and Cardia Cancer Registry reported a mean three year weight loss of 10.8% among disease-free patients, with 33.8% of this cohort demonstrating malnutrition at three years post-oesophagectomy. Mechanisms contributing to weight loss for disease-free patients after upper gastrointestinal surgery are poorly understood, however an association between increasing magnitude of weight loss and the presence of increased satiety is described. Our recent studies at SJH have demonstrated four fold elevated postprandial satiety gut hormone concentrations after oesophagectomy, compared with baseline preoperative values. Postprandial gut hormone levels correlate significantly with postprandial symptoms and altered appetite at 3 months postoperatively, and with body weight loss at 2 years postoperatively. However, the mechanism leading to exaggerated postprandial gut hormone production after upper gastrointestinal surgery is poorly understood, limiting targeted therapeutic options. In this study, we aim to characterise the role of altered nutrient transit and enteroendocrine cell function in the pathophysiology of excessive post-prandial gut hormone responses after upper gastrointestinal surgery. To do this, we will measure the gut hormone response to a standardised 400 kcal meal, as per previous studies, while concurrently assessing gastrointestinal transit time, and enteroendocrine cell morphology and function. In this way, we will determine whether the magnitude of the postprandial gut hormone response correlates with the rate of nutrient transit into the enteroendocrine L-cell rich small intestine, and whether enteroendocrine cell adaptation occurs after oesophagectomy. Furthermore, we have previously observed that gut hormone suppression using octreotide is associated with increased ad libitum among subjects after upper gastrointestinal cancer surgery (Elliott JA et al, Annals of Surgery, 2015). The mechanism of action of octreotide may relate to SSTR-5-mediated negative feedback to the enteroendocrine L-cell, but this medication may additionally reduce enteroendocrine L-cell responses through its inhibitory effect on gastrointestinal motility - reducing the rapidity with which nutrients are delivered to the small intestine - and small intestinal nutrient sensing via inhibition of the Na+-dependent glucose transporter SGLT-18-10. Through conduction of this double-blind, randomised, placebo-controlled crossover study, we aim to establish the mechanism of action of octreotide-mediated increased food intake in patients after gastrointestinal surgery. This may inform the design of future targeted interventions for this patient group.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date July 1, 2021
Est. primary completion date July 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patient group: 1. History of upper gastrointestinal surgery at least 9 months previously Control group: 1. Patients with suspected or confirmed non-dysplastic Barrett's oesophagus or reflux who are age, weight and gender matched to the patient cohort Exclusion Criteria: 1. Pregnancy, breastfeeding 2. Recurrent disease after surgery 3. Other active malignancy 4. Significant psychiatric disorder or cognitive decline or communication impairment limiting capacity to provide informed consent 5. Other disease or medication which may impact gut hormone physiology 6. Previous upper gastrointestinal resection 7. Certain allergies or dietary intolerances 8. Anticoagulants Patients with contraindications to the study medications (as per www.medicines.ie) will not be automatically excluded, but will be invited to participate in an attenuated protocol where that agent is not given. It is not anticipated that this will be a frequent occurrence, however this strategy will minimise unnecessary participant exclusion.

Study Design


Intervention

Drug:
Octreotide Acetate
50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
Saline Solution
Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
Paracetamol
Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge
Sulfasalazine
1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge
Diagnostic Test:
Duodenal biopsy
Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.

Locations

Country Name City State
Ireland Department of Surgery, St. James's Hospital Dublin
Ireland Wellcome Trust-Health Research Board Clinical Research Facility, St. James's Hospital Dublin

Sponsors (1)

Lead Sponsor Collaborator
St. James's Hospital, Ireland

Country where clinical trial is conducted

Ireland, 

References & Publications (2)

Elliott JA, Docherty NG, Eckhardt HG, Doyle SL, Guinan EM, Ravi N, Reynolds JV, Roux CWL. Weight Loss, Satiety, and the Postprandial Gut Hormone Response After Esophagectomy: A Prospective Study. Ann Surg. 2017 Jul;266(1):82-90. doi: 10.1097/SLA.0000000000001918. — View Citation

Elliott JA, Jackson S, King S, McHugh R, Docherty NG, Reynolds JV, le Roux CW. Gut Hormone Suppression Increases Food Intake After Esophagectomy With Gastric Conduit Reconstruction. Ann Surg. 2015 Nov;262(5):824-29; discussion 829-30. doi: 10.1097/SLA.0000000000001465. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Duodenal enteroendocrine cell density At one year post surgery, on the day of assessment
Other Duodenal enteroendocrine L-cell density At one year post surgery, on the day of assessment
Other Duodenal enteroendocrine cell mRNA expression profile At one year post surgery, on the day of assessment
Primary Area under the curve for paracetamol at 30 minutes after a 400kcal mixed meal stimulus 30 minutes post meal
Secondary Peak paracetamol level Within 300 minutes post meal
Secondary GLP-1 area under the curve over 300 minutes after a 400kcal mixed meal stimulus Within 300 minutes post meal
Secondary Glucose area under the curve over 300 minutes after a 400kcal mixed meal stimulus Within 300 minutes post meal
Secondary Insulin area under the curve over 300 minutes after a 400kcal mixed meal stimulus Within 300 minutes post meal
Secondary Visual analogue scales Within 300 minutes post meal
Secondary EORTC health related quality of life At one year post surgery, on the day of assessment
See also
  Status Clinical Trial Phase
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Enrolling by invitation NCT05534490 - Surgery and Functionality in Older Adults N/A
Recruiting NCT04792983 - Cognition and the Immunology of Postoperative Outcomes
Recruiting NCT04612491 - Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04204785 - Noise in the OR at Induction: Patient and Anesthesiologists Perceptions N/A
Completed NCT03432429 - Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study
Completed NCT04176822 - Designing Animated Movie for Preoperative Period N/A
Recruiting NCT05370404 - Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain: N/A
Not yet recruiting NCT05467319 - Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS Phase 3
Recruiting NCT04602429 - Children's Acute Surgical Abdomen Programme
Completed NCT03124901 - Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor N/A
Completed NCT04595695 - The Effect of Clear Masks in Improving Patient Relationships N/A
Recruiting NCT06103136 - Maestro 1.0 Post-Market Registry
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04059328 - Novel Surgical Checklists for Gynecologic Laparoscopy in Haiti
Recruiting NCT03697278 - Monitoring Postoperative Patient-controlled Analgesia (PCA) N/A
Completed NCT03355547 - Observation of Atelectasis Using Lung Ultrasonography in Children Undergoing General Anesthesia: the Cohort Study for Evaluation of the Relationship Between the Incidence and Severity of Upper Respiratory Tract Infection and the Magnitude of Anesthesia-induced Atelectasis
Recruiting NCT04776954 - Comparison of Normothermia Maintenance Between Resistive Blanket and Forced Air Warming Systems in Renal Transplant Surgery N/A